文献速递肝病消化道肿瘤与早癌

以干扰素为基础与无干扰素治疗对慢性丙型肝炎早期肝细胞癌发生和复发的影响

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
PubMed 文献 · J Hepatol · 2017-06-14

该回顾性研究基于1,897例慢性丙型肝炎患者的前瞻性数据库,其中1,145例接受以干扰素为基础治疗、752例接受无干扰素治疗。倾向性评分匹配分析显示两组早期肝细胞癌发生(p=0.49)和复发(p=0.54)率无显著差异。治疗后WFA+M2BP水平可能有助于评估无干扰素治疗后肝细胞癌风险。

要点

  • 倾向性评分匹配后,以干扰素为基础与无干扰素治疗的早期肝细胞癌发生(p=0.49)和复发(p=0.54)率无显著差异。
  • 治疗后甲胎蛋白(AFP)或WFA+M2BP水平较高与病毒清除后肝细胞癌发生和复发独立相关。
  • 在无严重纤维化患者中,仅治疗后WFA+M2BP水平与肝细胞癌发生和复发显著相关。

核心结论

  • 病毒清除后早期肝细胞癌发生和复发风险在以干扰素为基础与无干扰素治疗之间相似。
  • 治疗后WFA+M2BP水平可能是有助于评估无干扰素治疗后肝细胞癌风险的筛查生物标志物。
  • 抗病毒治疗后WFA+M2BP水平高的患者,即使无严重纤维化,也必须仔细随访肝细胞癌发生。

研究设计与样本

  • 对1,897例慢性丙型肝炎患者前瞻性数据库进行回顾性分析。
  • 患者接受以干扰素为基础治疗(1,145例)或无干扰素治疗(752例)。
  • 采用倾向性评分匹配分析比较累积肝细胞癌发生率和复发率。
  • 采用多因素分析识别病毒清除后肝细胞癌发生的预测因素。

主要发现

  • 倾向性评分匹配分析显示以干扰素为基础治疗组与无干扰素治疗组的肝细胞癌发生率无显著差异(p=0.49)。
  • 倾向性评分匹配分析显示以干扰素为基础治疗组与无干扰素治疗组的肝细胞癌复发率无显著差异(p=0.54)。
  • 多因素分析中,治疗后甲胎蛋白(AFP)或WFA+M2BP水平较高与病毒清除后肝细胞癌发生和复发独立相关。
  • 在无严重纤维化患者中,仅治疗后WFA+M2BP水平与肝细胞癌发生和复发显著相关。
  • ROC分析中WFA+M2BP水平的曲线下面积大于AFP水平的曲线下面积。

临床怎么用

  • 作者认为治疗后WFA+M2BP水平可能是有助于评估无干扰素治疗后肝细胞癌风险的筛查生物标志物。
  • 作者指出抗病毒治疗后WFA+M2BP水平高的患者,即使无严重纤维化,也必须仔细随访肝细胞癌发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although treatment for hepatitis C virus has been dramatically improved by the development of direct-acting antiviral agents (DAAs), whether interferon (IFN)-free therapy reduces hepatocarcinogenesis in an equivalent manner to IFN-based therapy remains controversial. The aims of this study were to evaluate the occurrence and recurrence of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients treated with DAAs and to identify biomarkers of HCC development after antiviral treatment. METHODS: A restrospective review of a prospective database of 1,897 CHC patients who were treated with IFN-based (1,145) or IFN-free therapies (752) was carried out. Cumulative HCC occurrence and recurrence rates were compared using propensity score-matched analysis. Predictors of HCC development after viral eradication were identified by multivariate analysis. RESULTS: Propensity score-matched analysis showed no significant difference in HCC occurrence (p=0.49) and recurrence rates (p=0.54) between groups treated with IFN-based or IFN-free therapies. In multivariate analysis, higher levels of post-treatment α-fetoprotein (AFP) or Wisteria floribunda agglutinin positive Mac-2 binding protein (WFA+M2BP) were independently associated with HCC occurrence and recurrence after viral eradication. Only post-treatment WFA+M2BP level was significantly associated with HCC occurrence and recurrence among patients without severe fibrosis. The area under the receiver operating characteristic (ROC) curve for WFA+M2BP levels was greater than that for AFP levels in ROC analysis. CONCLUSION: The risks of early HCC occurrence and recurrence after viral eradication were similar between IFN-based and IFN-free therapies. Post-treatment levels of WFA+M2BP may be helpful screening biomarkers for assessing the risk of HCC after IFN-free therapy. Patients with high WFA+M2BP levels after antiviral treatment, even without severe fibrosis, must be followed up carefully for HCC development. Lay summary: The risks of early HCC occurrence and recurrence after viral eradication were similar between IFN-based and IFN-free therapies. Post-treatment levels of WFA+M2BP may be helpful screening biomarkers for assessing the risk of HCC after IFN-free therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017. PMID: 28627363. doi:10.1016/j.jhep.2017.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。